Procarta
Desconocido
NAREB: Nanotherapeutics for antibiotic resistant emerging bacterial pathogens
PROCARTA BIOSYSTEMS LIMITED
participó en un
FP7:
Increase in antibiotic resistance is a global concern worldwide. The project NAREB's main objective is the optimization of several nanoformu...
Financiado
Financiado
DNA-TRAP: DNA TRAP Delivery of Nucleic Acid Based Therapeutics for the TReatment of Antibiotic Resistant Pat...
PROCARTA BIOSYSTEMS LIMITED
participó en un
FP7:
Antimicrobial agents, such as antibiotics, have dramatically reduced the number of deaths from infectious diseases over the last 70 years. H...
Financiado
Financiado
* No se disponen de datos de la empresa actual.